Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
Twist Bioscience Corp reported Fiscal year ended September 30, 2023 results: revenue $245.1 million, net income -$204.6 million, EPS -$3.60 per share.
- Period
- Fiscal year ended September 30, 2023
- Revenue
- $245.1 million
- Net income
- -$204.6 million
- EPS
- -$3.60 per share
- Result
- reported results
Exact text from the filing
FISCAL 2023 FINANCIAL RESULTS • Orders : Total orders received for fiscal 2023 grew to $264 million compared to $226.4 million for fiscal 2022. • Revenue : Total revenues for fiscal 2023 grew to $245.1 million compared to $203.6 million for fiscal 2022. • Cost of Revenues : Cost of revenues for fiscal 2023 grew to $155.4 million compared to $119.3 million for fiscal 2022. • Research and Development Expenses : Research and development expenses for fiscal 2023 decreased to $106.9 million compared to $120.3 million for fiscal 2022. • Selling, General and Administrative Expenses: Selling, general and administrative expenses for fiscal 2023 decreased to $189.7 million compared to $212.9 million for fiscal 2022. • Net Loss: Net loss attributable to common stockholders for fiscal 2023 decreased to $204.6 million , or $3.60 per share, compared to $217.9 million , or $4.04 per share, for fiscal 2022. • Cash Position: As of September 30, 2023 , the company had $336.4 million in cash, cash equiva
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
Twist Bioscience Corp reported Full year Fiscal 2024 results: revenue $285 million to $290 million. Guidance initiated.
- Period
- Full year Fiscal 2024
- Revenue
- $285 million to $290 million
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
— Expect revenue in the range of $285 million to $290 million for full year Fiscal 2024 --
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
Twist Bioscience Corp reported Three months ended September 30, 2023 results: revenue $66.9 million, net income -$46.2 million, EPS -$0.81 per share.
- Period
- Three months ended September 30, 2023
- Revenue
- $66.9 million
- Net income
- -$46.2 million
- EPS
- -$0.81 per share
- Result
- reported results
Exact text from the filing
FISCAL 2023 FOURTH QUARTER FINANCIAL RESULTS • Orders: Total orders received for the fourth quarter of fiscal 2023 grew to $71.1 million compared to $62.1 million for the same period of fiscal 2022 . • Revenue: Total revenues for the fourth quarter of fiscal 2023 grew to $66.9 million compared to $57.3 million for the same period of fiscal 2022 . • Cost of Revenues: Cost of revenues for the fourth quarter of fiscal 2023 increased to $42.4 million compared to $31.6 million for the same period of fiscal 2022 . • Research and Development Expenses: Research and development expenses for the fourth quarter of fiscal 2023 decreased to $23.7 million compared to $29.6 million for the same period of fiscal 2022 . • Selling, General and Administrative Expenses: Selling, general and administrative expenses for the fourth quarter of fiscal 2023 decreased to $47.4 million compared to $54.2 million for the same period of fiscal 2022 . • Net Loss: Net loss attributable to common stockholders for the f
View on SEC.gov